<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="52978"><DrugName>quizartinib dihydrochloride</DrugName><DrugNamesKey><Name id="43151663">Vanflyta</Name><Name id="42935856">quizartinib</Name><Name id="42935859">quizartinib dihydrochloride</Name></DrugNamesKey><DrugSynonyms><Name><Value>AB-200382</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AB-200432</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AB-200434</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Flt3 tyrosine kinase inhibitors, Ambit</Value></Name><Name><Value>AB-200243</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AC-220</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AB-515</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AB-460</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AC-886</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Flt3 tyrosine kinase inhibitors, Ambit/Astellas</Value></Name><Name><Value>AB-530</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>quizartinib</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>quizartinib dihydrochloride</Value><Types><Type>USAN</Type></Types></Name><Name><Value>ASP-2689</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Vanflyta</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>950769-58-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="29179">Ambit Biosciences Corp</CompanyOriginator><CompaniesPrimary><Company id="1017506">Daiichi Sankyo Co Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="1013295">Astellas Pharma Inc</Company><Company id="29179">Ambit Biosciences Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="52978" type="Drug"><TargetEntity id="394490" type="siDrug">AB-200434</TargetEntity><TargetEntity id="443269" type="siDrug">Quizartinib</TargetEntity></SourceEntity><SourceEntity id="1013295" type="Company"><TargetEntity id="4295876965" type="organizationId">Astellas Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="1017506" type="Company"><TargetEntity id="4295880584" type="organizationId">Daiichi Sankyo Co Ltd</TargetEntity></SourceEntity><SourceEntity id="29179" type="Company"><TargetEntity id="4296869940" type="organizationId">Ambit Biosciences Corp</TargetEntity></SourceEntity><SourceEntity id="1731" type="ciIndication"><TargetEntity id="D015470" type="MeSH"/><TargetEntity id="519" type="ORPHANET"/><TargetEntity id="-1550871001" type="omicsDisease"/><TargetEntity id="686" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"/></SourceEntity><SourceEntity id="3806" type="Action"><TargetEntity id="1910" type="Mechanism">Anti-CD135 (flt-3)</TargetEntity><TargetEntity id="1628" type="Mechanism">Flt3 (FLK2/STK1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="948" type="Action"><TargetEntity id="1789" type="Mechanism">Platelet-Derived Growth Factor (PDGF) Inhibitors</TargetEntity><TargetEntity id="1072" type="Mechanism">PDGFR Family Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3808" type="Action"><TargetEntity id="3405" type="Mechanism">Anti-c-KIT</TargetEntity><TargetEntity id="5665" type="Mechanism">KIT (C-KIT) (Asp816Val Mutant) Inhibitors</TargetEntity><TargetEntity id="1704" type="Mechanism">KIT (C-KIT) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="PTGT-00762" type="ciTarget"><TargetEntity id="212861059123223" type="siTarget">Receptor-type tyrosine-protein kinase FLT3</TargetEntity><TargetEntity id="7001" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-01208" type="ciTarget"><TargetEntity id="87400752538153" type="siTarget">Mast/stem cell growth factor receptor Kit</TargetEntity><TargetEntity id="441" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="R">Registered</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1731">Acute myelogenous leukemia</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="651">Cancer</Indication><Indication id="725">Solid tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="3808">Kit tyrosine kinase inhibitor</Action><Action id="3806">Flt3 tyrosine kinase inhibitor</Action><Action id="948">PDGF receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="1589">Apoptosis stimulator</Action><Action id="62255">Anticancer protein kinase inhibitor</Action><Action id="7293">Synergist</Action></ActionsSecondary><Technologies><Technology id="595">Tablet formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="746">Solution</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-07-01T08:35:06.000Z</LastModificationDate><ChangeDateLast>2019-06-24T00:00:00.000Z</ChangeDateLast><AddedDate>2005-03-24T12:02:38.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1017506" linkType="Company"&gt;Daiichi Sankyo&lt;/ulink&gt;, following its acquisition of &lt;ulink linkID="29179" linkType="Company"&gt;Ambit&lt;/ulink&gt;, has developed quizartinib dihydrochloride (Vanflyta; AC-220; ASP-2689), an FLT3/(internal tandem duplications) ITD inhibitor and the lead candidate  from a series of Flt3 and Kit tyrosine kinase inhibitors [&lt;ulink linkID="1064894" linkType="Reference"&gt;1064894&lt;/ulink&gt;],    [&lt;ulink linkID="587118" linkType="Reference"&gt;587118&lt;/ulink&gt;], [&lt;ulink linkID="678567" linkType="Reference"&gt;678567&lt;/ulink&gt;], [&lt;ulink linkID="1629997" linkType="Reference"&gt;1629997&lt;/ulink&gt;]. The drug is indicated in Japan for the treatment of adults with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML), as detected by a Ministry of Health, Labor and Welfare (MHLW)-approved test  [&lt;ulink linkID="2165456" linkType="Reference"&gt;2165456&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2019, the drug was approved in Japan for relapsed/refractory FLT3-ITD AML [&lt;ulink linkID="2165456" linkType="Reference"&gt;2165456&lt;/ulink&gt;].  In November 2018, the FDA accepted an NDA for Priority Review for the treatment of relapsed/refractory FLT3-ITD AML based on the QuANTUM-R study. At that time, a decision was expected on May 25, 2019 [&lt;ulink linkID="2097040" linkType="Reference"&gt;2097040&lt;/ulink&gt;]; in April 2019, the FDA extended the review period for the NDA  to allow time to review additional data the agency had requested,  with a new PDUFA date set for August 25, 2019 [&lt;ulink linkID="2138214" linkType="Reference"&gt;2138214&lt;/ulink&gt;]; however, in May 2019, the FDA's ODAC voted 8 to 3 against the benefits of the drug outweighing its risks [&lt;ulink linkID="2151584" linkType="Reference"&gt;2151584&lt;/ulink&gt;], and  in June 2019, the company received a Complete Response Letter (CRL) from the FDA and at that time was evaluating the next steps [&lt;ulink linkID="2166873" linkType="Reference"&gt;2166873&lt;/ulink&gt;]. In November 2018, the EMA accepted a MAA with accelerated assessment for relapsed or refractory FLT3-ITD  AML [&lt;ulink linkID="2090035" linkType="Reference"&gt;2090035&lt;/ulink&gt;];  in January 2019, the EMA's CHMP recommended a scientific discussion together with a list of questions [&lt;ulink linkID="2140441" linkType="Reference"&gt;2140441&lt;/ulink&gt;]. In September 2016, a phase III trial (QuANTUM-First)  was initiated in first-line FLT3-ITD-positive AML [&lt;ulink linkID="1793198" linkType="Reference"&gt;1793198&lt;/ulink&gt;]; in June 2019, the trial was ongoing [&lt;ulink linkID="2166873" linkType="Reference"&gt;2166873&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The company is also investigating quizartinib in combination with   &lt;ulink linkID="33494" linkType="Drug"&gt;milademetan&lt;/ulink&gt;    [&lt;ulink linkID="2045752" linkType="Reference"&gt;2045752&lt;/ulink&gt;], [&lt;ulink linkID="2041921" linkType="Reference"&gt;2041921&lt;/ulink&gt;];  in August 2018, a phase I trial of the combination began in patients with FLT3-ITD mutant AML that was relapsed/refractory, or newly diagnosed and unfit for intensive chemotherapy  [&lt;ulink linkID="2043914" linkType="Reference"&gt;2043914&lt;/ulink&gt;]; in June 2019, the trial was ongoing [&lt;ulink linkID="2166873" linkType="Reference"&gt;2166873&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1013295" linkType="Company"&gt;&lt;/ulink&gt;Ambit and former licensee &lt;ulink linkID="1013295" linkType="Company"&gt;Astellas&lt;/ulink&gt; were previously codeveloping quizartinib  for the potential treatment of solid tumors [&lt;ulink linkID="1064894" linkType="Reference"&gt;1064894&lt;/ulink&gt;],    [&lt;ulink linkID="587118" linkType="Reference"&gt;587118&lt;/ulink&gt;], [&lt;ulink linkID="678567" linkType="Reference"&gt;678567&lt;/ulink&gt;], [&lt;ulink linkID="678860" linkType="Reference"&gt;678860&lt;/ulink&gt;]. In January 2010, a phase I trial  for solid tumor was initiated   [&lt;ulink linkID="1072476" linkType="Reference"&gt;1072476&lt;/ulink&gt;]. By March 2013, the drug was no longer being developed for solid tumors [&lt;ulink linkID="1394638" linkType="Reference"&gt;1394638&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;The drug has patent coverage until at least March 2027 in the US, Europe and Japan [&lt;ulink linkID="PA6262501" linkType="Patent"&gt;US-08129374&lt;/ulink&gt;], [&lt;ulink linkID="PA6863679" linkType="Patent"&gt;US-08557810&lt;/ulink&gt;], [&lt;ulink linkID="PA7886326" linkType="Patent"&gt;US-08921546&lt;/ulink&gt;], [&lt;ulink linkID="PA3725523" linkType="Patent"&gt;EP-02001892&lt;/ulink&gt;], [&lt;ulink linkID="PA5398458" linkType="Patent"&gt;JP-04610668&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;in October 2016, launch was expected prior to fiscal 2020 [&lt;ulink linkID="1864580" linkType="Reference"&gt;1864580&lt;/ulink&gt;]; in October 2018, Daiichi aimed at preparing a successful launch of quizartinib in 2019 [&lt;ulink linkID="2082962" linkType="Reference"&gt;2082962&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;By April 2014, the FDA had granted Orphan Drug status for AML [&lt;ulink linkID="1543632" linkType="Reference"&gt;1543632&lt;/ulink&gt;]. By October 2016, quizartinib had been granted US Fast Track designation by the FDA for relapsed/refractory AML [&lt;ulink linkID="1806143" linkType="Reference"&gt;1806143&lt;/ulink&gt;]. In August 2018, the FDA granted Breakthrough Therapy designation for the treatment of adults with relapsed/refractory FLT3-ITD AML, based on the results of the phase III QuANTUM-R study [&lt;ulink linkID="2058908" linkType="Reference"&gt;2058908&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2013, a Type C meeting with the FDA was held. At that time, the FDA requested additional information and analyses to be presented at end of Phase II meeting in November 2013 [&lt;ulink linkID="1464808" linkType="Reference"&gt;1464808&lt;/ulink&gt;]. In December 2013, following the meeting, the FDA disagreed that  complete remission with incomplete hematologic recovery represented a surrogate endpoint likely to predict clinical benefit for the purpose of accelerated approval [&lt;ulink linkID="1505816" linkType="Reference"&gt;1505816&lt;/ulink&gt;]. In May 2018, Daiichi Sankyo planned to initiate worldwide regulatory submissions based on positive data from the QuANTUM-R trial [&lt;ulink linkID="2031310" linkType="Reference"&gt;2031310&lt;/ulink&gt;]. In November 2018, the FDA accepted an NDA and granted Priority Review for the treatment of adults with relapsed/refractory FLT3-ITD AML based on the QuANTUM-R study. At that time, a decision was expected on May 25, 2019 [&lt;ulink linkID="2097040" linkType="Reference"&gt;2097040&lt;/ulink&gt;]; in April 2019, the FDA extended the review period for the NDA  to allow time to review additional data the agency had requested,  with a new PDUFA date set for August 25, 2019 [&lt;ulink linkID="2138214" linkType="Reference"&gt;2138214&lt;/ulink&gt;]. However, in May 2019, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 8 to 3 against the benefit of the drug outweighing its risks [&lt;ulink linkID="2151584" linkType="Reference"&gt;2151584&lt;/ulink&gt;]. In June 2019, the company received a CRL from the FDA and at that time was evaluating the next steps [&lt;ulink linkID="2166873" linkType="Reference"&gt;2166873&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In May 2018, Daiichi Sankyo planned to initiate worldwide regulatory submissions based on positive data from the QuANTUM-R trial [&lt;ulink linkID="2031310" linkType="Reference"&gt;2031310&lt;/ulink&gt;]. In November 2018, the EMA accepted the MAA with accelerated assessment for quizartinib, for the treatment of adults with relapsed or refractory FLT3-ITD  AML [&lt;ulink linkID="2090035" linkType="Reference"&gt;2090035&lt;/ulink&gt;]. In January 2019, the EMA's CHMP recommended a scientific discussion together with a list of questions [&lt;ulink linkID="2140441" linkType="Reference"&gt;2140441&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  February  2009, the EMA's COMP adopted a positive opinion on granting Orphan status for AML [&lt;ulink linkID="989804" linkType="Reference"&gt;989804&lt;/ulink&gt;]; by April 2014, the EC had granted Orphan Drug status [&lt;ulink linkID="1543632" linkType="Reference"&gt;1543632&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In October 2018, an NDA was filed in Japan with the MHLW for the treatment of relapsed or refractory FLT3-ITD AML, based on the phase III QuANTUM-R study results, and including data from phase II study in Japan [&lt;ulink linkID="2083462" linkType="Reference"&gt;2083462&lt;/ulink&gt;]. By November 2018, the NDA had been granted accelerated review [&lt;ulink linkID="2090035" linkType="Reference"&gt;2090035&lt;/ulink&gt;]. In June 2019, the drug was approved in Japan for the treatment of adults with relapsed/refractory FLT3-ITD AML [&lt;ulink linkID="2165456" linkType="Reference"&gt;2165456&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2018, the Japanese Ministry of Health, Labour and Welfare (MHLW) Second Committee on New Drugs, Pharmaceutical Affairs and Food Sanitation Council recommended Orphan Drug designation for FLT3 mutation-positive AML [&lt;ulink linkID="2062137" linkType="Reference"&gt;2062137&lt;/ulink&gt;]. In September 2018, the MHLW granted Orphan Drug designation for FLT3-mutated AML [&lt;ulink linkID="2071460" linkType="Reference"&gt;2071460&lt;/ulink&gt;], [&lt;ulink linkID="2124357" linkType="Reference"&gt;2124357&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In October 2018, new postmarketing surveillance on quizartinib following the revised Good Post-marketing Study Practice (GPSP) criteria was planned to be designed by March 2019 [&lt;ulink linkID="2082962" linkType="Reference"&gt;2082962&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;First-line AML&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In September 2016, a randomized, double-blind, placebo-controlled, phase III study (&lt;ulink linkID="252113" linkType="Protocol"&gt;NCT02668653&lt;/ulink&gt;; QuANTUM-First; CTR20170661) was initiated in the US, Australia, Europe, Canada, South America, Israel,   Far East, Japan, South Korea, China, Hong Kong,  Singapore and Taiwan, that would compare quizartinib administered with standard induction and consolidation chemotherapy, then administered as a maintenance therapy, versus placebo in patients with untreated FLT3-ITD-positive AML. The primary endpoint was PFS.  The trial was expected to enroll 536 patients and complete in January 2020   [&lt;ulink linkID="1730984" linkType="Reference"&gt;1730984&lt;/ulink&gt;], [&lt;ulink linkID="1793198" linkType="Reference"&gt;1793198&lt;/ulink&gt;], [&lt;ulink linkID="1806143" linkType="Reference"&gt;1806143&lt;/ulink&gt;]. In October 2016, the first patient was enrolled [&lt;ulink linkID="1806143" linkType="Reference"&gt;1806143&lt;/ulink&gt;]. In June 2017, the trial was also planned in China (expected n = 48) [&lt;ulink linkID="1941827" linkType="Reference"&gt;1941827&lt;/ulink&gt;]. In September 2017, enrollment was underway at 167 of approximately 275 expected sites worldwide [&lt;ulink linkID="1960485" linkType="Reference"&gt;1960485&lt;/ulink&gt;]. In October 2018, the trial was ongoing [&lt;ulink linkID="2082962" linkType="Reference"&gt;2082962&lt;/ulink&gt;]. In June 2019, the trial was ongoing [&lt;ulink linkID="2166873" linkType="Reference"&gt;2166873&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Relapsed/refractory AML&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In December 2013, following the FDA feedback, the company planned to initiate a randomized, controlled, phase III trial in relapsed and/or refractory FLT3-ITD positive AML patients [&lt;ulink linkID="1505816" linkType="Reference"&gt;1505816&lt;/ulink&gt;]. In April 2014, patient (n = 367) enrollment in the registrational,   follow-on, investigator-sponsored phase III trial (&lt;ulink linkID="168987" linkType="Protocol"&gt;NCT02039726&lt;/ulink&gt;; AC220-007, &lt;ulink linkID="168987" linkType="Protocol"&gt;EudraCT Number 2013-004890-28&lt;/ulink&gt;; QUANTUM-R) began in the US, Western Europe, Canada and Australia, Hong Kong, Singapore and Taiwan. The primary outcome was overall survival. The trial would evaluate quizartinib monotherapy compared with chemotherapy salvage therapy in patients with AML who are refractory or have relapsed within 6 months of first-line AML therapy  [&lt;ulink linkID="1537429" linkType="Reference"&gt;1537429&lt;/ulink&gt;], [&lt;ulink linkID="1543910" linkType="Reference"&gt;1543910&lt;/ulink&gt;], [&lt;ulink linkID="1543632" linkType="Reference"&gt;1543632&lt;/ulink&gt;], [&lt;ulink linkID="1544128" linkType="Reference"&gt;1544128&lt;/ulink&gt;],  [&lt;ulink linkID="1806143" linkType="Reference"&gt;1806143&lt;/ulink&gt;], [&lt;ulink linkID="1730984" linkType="Reference"&gt;1730984&lt;/ulink&gt;]. In October 2015, the protocol was approved in Korea [&lt;ulink linkID="1671541" linkType="Reference"&gt;1671541&lt;/ulink&gt;]; recruitment  began in October 2016 [&lt;ulink linkID="1544128" linkType="Reference"&gt;1544128&lt;/ulink&gt;], [&lt;ulink linkID="1806143" linkType="Reference"&gt;1806143&lt;/ulink&gt;]. In April 2017, continuation of the study was approved following the recommendations from an  independent data monitoring committee  interim analysis [&lt;ulink linkID="1982937" linkType="Reference"&gt;1982937&lt;/ulink&gt;]. In May 2018, topline results were reported. Quizartinib met its primary endpoint of significantly prolonging OS compared with chemotherapy [&lt;ulink linkID="2031310" linkType="Reference"&gt;2031310&lt;/ulink&gt;]. In June 2018, further data were presented at 23rd EHA Annual Congress in Stockholm, Sweden. The HR for OS in patients treated with quizartinib relative to salvage chemotherapy was 0.76. At week 52, estimated survival probability was 27 and 20% in quizartinib and salvage chemotherapy arms, respectively [&lt;ulink linkID="2045683" linkType="Reference"&gt;2045683&lt;/ulink&gt;], [&lt;ulink linkID="2041921" linkType="Reference"&gt;2041921&lt;/ulink&gt;], [&lt;ulink linkID="2045310" linkType="Reference"&gt;2045310&lt;/ulink&gt;]. In July 2018, the trial was ongoing, but was no longer recruiting participants. By that time, completion was expected in July 2019 [&lt;ulink linkID="1543910" linkType="Reference"&gt;1543910&lt;/ulink&gt;].   In December 2018, final data were presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA. In quizartinib and salvage chemotherapy (SC) arms, the median OS was 6.2 and 4.7 months, respectively; and the median event-free survival was 6.0 and 3.7 weeks, respectively (HR was 0.90; p = 0.1071). In both arms, the most common grade &amp;gt;/= 3 TEAEs reported were infections and those associated with cytopenia [&lt;ulink linkID="2098879" linkType="Reference"&gt;2098879&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In August 2018, an open-label, dose-escalation, sequential-assignment, phase I/II trial (&lt;ulink linkID="343515" linkType="Protocol"&gt;NCT03793478&lt;/ulink&gt;; AC220-A-U202; 2016-002919-18) was initiated in Europe and Israel to assess quizartinib in combination With re-induction chemotherapy, and as single-agent maintenance therapy, in pediatric and young adult patients (expected n = 65) aged from 1 month to 21 Years with relapsed/refractory AML with FLT3-ITD mutations. The primary endpoint was composite complete remission (CRc) rate. The trial was expected to complete in May 2027 [&lt;ulink linkID="2151823" linkType="Reference"&gt;2151823&lt;/ulink&gt;]. In June 2019, the trial was ongoing in the US and  Europe [&lt;ulink linkID="2166873" linkType="Reference"&gt;2166873&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2018, data from a post hoc exploratory analysis of two phase II, open-label studies (study A, NCT00989261 and study B, NCT01565668) of quizartinib in FLT3-ITD-mutated relapsed/refractory AML patients, who were previously treated with prior FLT3 tyrosine kinase inhibitors (TKIs), were presented at the 23rd EHA Annual Congress in Stockholm, Sweden. In study A, CRc and ORR with quizartinib were 33 and 67%, respectively, in prior TKI-treated patients relative to 53 and 75%, respectively, in TKI-naive patients. In study B, CRc and ORR were 36 and 45%, respectively, in prior TKI-treated patients relative to 48 and 69%, respectively, in TKI-naive patients. In prior TKI-treated and TKI-naive patients, median OS was 24.6 and 24.7 weeks, respectively, in study A; and 20.9 and 23.7 weeks, respectively, in study B. Across both subgroups, patients who attained CRc with quizartinib showed a longer median OS when compared with patients who did not attain CRc [&lt;ulink linkID="2045658" linkType="Reference"&gt;2045658&lt;/ulink&gt;], [&lt;ulink linkID="2041921" linkType="Reference"&gt;2041921&lt;/ulink&gt;]. In June 2018, further data were presented at the 54th ASCO Annual Meeting in Chicago, IL. Febrile neutropenia, acute myeloid leukemia, anemia, pneumonia, fatigue and neutropenia were some of the grade &amp;gt;/= 3 treatment emergent adverse events reported in &amp;gt;/= 10% of patients in both studies A and B [&lt;ulink linkID="2039831" linkType="Reference"&gt;2039831&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2016, an open-label phase II study (&lt;ulink linkID="281397" linkType="Protocol"&gt;NCT02984995&lt;/ulink&gt;) began to evaluate quizartinib monotherapy in Japanese patients with FLT3-ITD-positive refractory or relapsed AML. The primary endpoint was compositie complete remission (CRc) rate. The trial was to enroll 41 patients and complete in March 2019 [&lt;ulink linkID="1894090" linkType="Reference"&gt;1894090&lt;/ulink&gt;]. In October 2018, it was reported at an interim analysis that the study met its primary endpoint, which triggered an early stop due to efficacy [&lt;ulink linkID="2083462" linkType="Reference"&gt;2083462&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2014, a follow-on phase II  trial in pediatric patients was planned [&lt;ulink linkID="1537429" linkType="Reference"&gt;1537429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2013, an open-label, interventional, non-randomized, parallel-assignment, phase I/II (&lt;ulink linkID="144653" linkType="Protocol"&gt;NCT01892371&lt;/ulink&gt;; 2012-1047) to assess the safety and efficacy of AC-220 in combination with &lt;ulink linkID="37370" linkType="Drug"&gt;5-azacitidine&lt;/ulink&gt; or low-dose &lt;ulink linkID="70185" linkType="Drug"&gt;cytarabine&lt;/ulink&gt; in patients (n = 64) with relapsed or refractory AML or myelodysplastic syndrome was initiated in the US. At that time, the trial was expected to be completed in November 2018. The trial would include previously untreated FLT3-ITD-positive AML patients age 60 or older, or FLT3-ITD-positive AML patients 18 years of age or older in first relapse [&lt;ulink linkID="1459720" linkType="Reference"&gt;1459720&lt;/ulink&gt;]. In April 2014, the two-arm, phase I portion of the trial in 12 patients was completed and data showed the combination regimens were tolerated and there were no early mortalities. At that time, the phase II part of the trial was initiated  [&lt;ulink linkID="1543632" linkType="Reference"&gt;1543632&lt;/ulink&gt;]. In December 2014, further data were presented at the 56th ASH Meeting in San Francisco, CA. The objective response rate   was 82% and 18 patients (13 from 5-azacitidine and 5 from cytarabine) had responded. Hypokalemia, hypophosphatemia, hyponatremia and  hypocalcemia were some of the grade 3/4 toxicities observed  [&lt;ulink linkID="1635314" linkType="Reference"&gt;1635314&lt;/ulink&gt;]. In December 2017, further data were presented at the 59th ASH Annual Meeting and Exposition in Atlanta, GA. In quizartinib + azacitidine and quizartinib + low-dose cytarabine treatment groups, median overall survival was 14.8 and 7.4 months, respectively (p = 0.390); and relapse-free survival was 6.93 and 4.37 months, respectively (p = 0.963). At the end of study, of 26 patients, 7 patients had newly identified FLTT3 D835 mutations. At the time of presentation, accrual to the study was ongoing [&lt;ulink linkID="1988952" linkType="Reference"&gt;1988952&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2012, a dose-finding, open-label phase IIb trial in relapse/refractory FLT3 ITD-positive AML  parallel assignment, randomized study (&lt;ulink linkID="86071" linkType="Protocol"&gt;NCT01565668&lt;/ulink&gt;, 2689-CL-2004, 2011-005408-13) was initiated in the US and Europe [&lt;ulink linkID="1298082" linkType="Reference"&gt;1298082&lt;/ulink&gt;]. By August 2013, topline analyses of 30 and 60mg doses had been completed and data were reported. Grade 3 QTc rate was reduced at lower doses [&lt;ulink linkID="1464808" linkType="Reference"&gt;1464808&lt;/ulink&gt;]. In December 2013,  data from 76 patients were presented at the 55th ASH Meeting in New Orleans, LA. CRc was achieved by 36 patients with CR in 3 patients, CRp in 1 patient and CRi in 32 patients. Partial response was achieved by 14 patients. At 30 and 60 mg dose levels, the median duration of CRc was 4.1 and 20.0 weeks, respectively and the median overall survival duration was 20.7 and 25.4 weeks, respectively [&lt;ulink linkID="1503587" linkType="Reference"&gt;1503587&lt;/ulink&gt;] [&lt;ulink linkID="1507456" linkType="Reference"&gt;1507456&lt;/ulink&gt;]. In June 2014, data were presented at the 50th ASCO meeting in Chicago, IL. A total of 28 of 76 patients underwent HSCT and of these 23 had achieved a CRc and 4 patients achieved a PR prior to HSCT. In the 30- and 60-mg quizartinib groups, patients who underwent HSCT had an OS of 31 and 28.1 weeks, respectively, compared with 19 and 16.3 weeks, respectively, for patients who did not receive HSCT [&lt;ulink linkID="1562945" linkType="Reference"&gt;1562945&lt;/ulink&gt;], [&lt;ulink linkID="1562947" linkType="Reference"&gt;1562947&lt;/ulink&gt;], [&lt;ulink linkID="1565282" linkType="Reference"&gt;1565282&lt;/ulink&gt;]. In June 2014, data  were presented at the 19th EHA Congress in Milan, Italy.  Subjects (n = 76) received quizartinib (30 or 60 mg/day). Patients randomized to 30 mg/day quizartinib and who underwent HSCT had an OS of 31 weeks compared to 19 weeks for patients without HSCT; patients treated with 60 mg/day and who underwent HSCT had an OS of 28.1 weeks compared to 16.3 weeks for patients without HSCT.  Further follow-up  showed that  24 subjects were alive at &amp;gt; 24 weeks with 4 subjects alive  &amp;gt; 12 months. Of the 4 subjects, 2  were bridged to a HSCT immediately after quizartinib treatment, and 1 of the 4 subjects remained on study taking quizartinib for over 1 year [&lt;ulink linkID="1567023" linkType="Reference"&gt;1567023&lt;/ulink&gt;],  [&lt;ulink linkID="1568623" linkType="Reference"&gt;1568623&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2009, a phase II, single-arm, multinational, 180-patient  study (&lt;ulink linkID="60833" linkType="Protocol"&gt;NCT00989261&lt;/ulink&gt;; AC220-002; ACE) began in the US, Canada and  Europe. FLT3 ITD-positive AML patients aged 60 or over who had relapsed or were refractory after first-line treatment, or patients aged 18 years and over who had relapsed or were refractory after second-line treatment would receive quizartinib  200 mg po qd. The primary endpoints would be overall composite complete remission rate and complete remission rate, while the secondary endpoints would include progression-free survival, overall survival, duration of remission, safety and tolerability [&lt;ulink linkID="1063672" linkType="Reference"&gt;1063672&lt;/ulink&gt;], [&lt;ulink linkID="1942367" linkType="Reference"&gt;1942367&lt;/ulink&gt;]. 	By May 2011, 240 patients had been enrolled  [&lt;ulink linkID="1196517" linkType="Reference"&gt;1196517&lt;/ulink&gt;]. In June 2011, interim data from the first 62 patients (25 aged 60 or over and 37 aged 18 or over)  in this trial were presented at the 16th EHA meeting in London, UK. Of these 62 patients, 53 were evaluable for efficacy; overall composite complete response was &amp;gt;40%, with a higher response (&amp;gt; 60%) observed in those patients refractory to chemotherapy. Median survival for all patients was 24.6 weeks. The most common adverse effects were febrile neutropenia and asymptomatic QTc progression [&lt;ulink linkID="1198250" linkType="Reference"&gt;1198250&lt;/ulink&gt;], [&lt;ulink linkID="1199431" linkType="Reference"&gt;1199431&lt;/ulink&gt;]. In December 2011, further  data were presented at the 53rd American Society of Hematology (ASH) meeting in San Diego, CA. Overall, the respective rates of complete remission (CR), confirmed rate of CR with incomplete platelet recovery (CRp) and CR with incomplete hematological recovery (CRi) were 4, 4 and 39% in the cohort 1 and 0, 0 and 36% in the cohort 2; the composite CR (CRc) rates were 46 and 36% in cohorts 1 and 2, respectively. Overall, 12 patients (4 in cohort 1 and 8 in cohort 2) showed partial responses (PR). The median survival duration of patients in cohorts 1 and 2 was 24.1 and 26.9 weeks, respectively;  the respective median survival duration of patients who showed CRc and PR was 34.1 ad 26.6 weeks  [&lt;ulink linkID="1243620" linkType="Reference"&gt;1243620&lt;/ulink&gt;].  In December 2012, final data were presented from the confirmatory phase of the study in 271 patients at the 54th ASH Annual Meeting and Exposition in Atlanta, GA. For the FLT3-ITD-positive (n = 92) and –negative (n = 41) patients aged 60 or over, the rates of composite complete remission (CRc) were 53 and 36%, with a median duration of response of 12.7 and 22.1 weeks, respectively; the median overall survival was 25.3 and 19.0 weeks, respectively. For the FLT3-ITD-positive (n = 100) and –negative (n = 72) patients aged 18 or over, the CRcs were 46 and 32%, with a median duration of response of 12.1 and 7 weeks, respectively, and the median overall survival was 22.9 and 25.6 weeks, respectively [&lt;ulink linkID="1347869" linkType="Reference"&gt;1347869&lt;/ulink&gt;], [&lt;ulink linkID="1349155" linkType="Reference"&gt;1349155&lt;/ulink&gt;]. Data in  a subgroup of patients (n = 137) with FLT3-ITD positive or negative relapsed/refractory AML after second-line chemotherapy or hematopoietic stem cell transplantation at the 54th ASH Meeting in Atlanta, GA. For patients with FLT3-ITD(+) AML (n = 99),  the composite complete remission (CRc) rate was 44% (4% showed CR, and 40% had CR with incomplete hematologic recovery (CRi)), with a median overall survival of 23.1 weeks. For patients with FLT3-ITD(-) AML (n = 38), CRc rate was 34% (CR, CR with incomplete platelet recovery and CRi were achieved by 3, 3, and 29% of patients, respectively), with a median overall survival of 25.6 weeks [&lt;ulink linkID="1346249" linkType="Reference"&gt;1346249&lt;/ulink&gt;]. In June 2013, further data from subgroup analysis of this study in 176 patients were presented at the 49th ASCO meeting in Chicago, IL. The CRc and partial response (PR) rates were 46 and 20% in the FLT-3-ITD-positive group and 30 and 15% in the FLT-3-ITD-negative group, respectively. A total of 47 FLT-3-ITD-positive patients underwent HSCT after quizartinib therapy; median overall survival of these patients with either CRc or PR was 34.1 weeks compared with 24.1 weeks for the 56 patients who achieved CRc or PR but did not undergo HSCT. Of the FLT-3-ITD-positive patients, 27 survived for &amp;gt; 12 months   [&lt;ulink linkID="1425079" linkType="Reference"&gt;1425079&lt;/ulink&gt;], [&lt;ulink linkID="1426052" linkType="Reference"&gt;1426052&lt;/ulink&gt;], [&lt;ulink linkID="1433035" linkType="Reference"&gt;1433035&lt;/ulink&gt;]. Further data from subgroup analysis of 154 patients aged &amp;gt;/= 65 years with FLT-3 internal tandem duplication (ITD)-positive or negative AML relapsed/refractory to first-line therapy were presented at the same meeting. In  the FLT-3-ITD-positive and negative groups, 57 and 36% of patients showed composite complete remission, and 7% of patients in both groups showed composite complete remission and complete response; the  overall survival duration was  25.3 and 19.1 months, respectively, and the one-year survival rates were 17.3 and 13.6%, respectively [&lt;ulink linkID="1425088" linkType="Reference"&gt;1425088&lt;/ulink&gt;], [&lt;ulink linkID="1433035" linkType="Reference"&gt;1433035&lt;/ulink&gt;], [&lt;ulink linkID="1426052" linkType="Reference"&gt;1426052&lt;/ulink&gt;]. Further data from subgroup analysis of this study in 83 patients aged &amp;gt;/= 70 years with FLT-3-ITD-positive or negative AML relapsed/refractory to first-line therapy, second-line chemotherapy or HSCT were presented at the same meeting. The CRc and CR rates were 53 and 2% in the FLT-3-ITD-positive group and 43 and 9% in the FLT-3-ITD-negative group, respectively. The median overall survival duration was 21.0 and 19.0 weeks in the FLT-3-ITD-positive and negative groups, respectively [&lt;ulink linkID="1425090" linkType="Reference"&gt;1425090&lt;/ulink&gt;], [&lt;ulink linkID="1433035" linkType="Reference"&gt;1433035&lt;/ulink&gt;], [&lt;ulink linkID="1426052" linkType="Reference"&gt;1426052&lt;/ulink&gt;].  In June 2014, data were presented at the 50th ASCO meeting in Chicago, IL. A total of 47 of 136 patients underwent HSCT; of these 26 had achieved composite complete response (CRc) and 18 had PR prior to HSCT. Patients who underwent HSCT had a median overall survival (OS) of 34.1 weeks and a one-year survival rate of 36% compared with 18.4 weeks and 12%, respectively, for patients who did not receive HSCT [&lt;ulink linkID="1562945" linkType="Reference"&gt;1562945&lt;/ulink&gt;]. In June 2014, further  data were presented at the 19th EHA Congress in Milan, Italy. Complete composite  and partial responses were observed in 36 and 14 patients, respectively. Median survival was 20.9 and 25.4 weeks for the quizartinib 30 and 60 mg dose groups, respectively. Brigde to transplant rate was seen in 32 and 42% of the patients in the quizartinib 30 and 60 mg dose groups, respectively [&lt;ulink linkID="1567026" linkType="Reference"&gt;1567026&lt;/ulink&gt;], [&lt;ulink linkID="1568623" linkType="Reference"&gt;1568623&lt;/ulink&gt;]. Patients (n = 136) received quizartinib at a initial starting dose of 200 mg which was reduced to 135 and 90 mg in males and females, respectively due to QTcF prolongation. A total of 47 patients proceeded to HSCT and of these 26 achieved a complete response and 18 achieved a partial response prior to HSCT. Median overall survival (OS) was 34.1 weeks and 1-year survival rate was 36% [&lt;ulink linkID="1567023" linkType="Reference"&gt;1567023&lt;/ulink&gt;],  [&lt;ulink linkID="1568623" linkType="Reference"&gt;1568623&lt;/ulink&gt;].  In December 2015, further data were presented at the 57th ASH Annual Meeting and Exposition in Orlando, FL. In quizartinib versus the National Cancer Research Institute (NCRI) database cohort, the respective remission rate was 43 versus 11% and the median survival was 159 versus 56 days, respectively with a hazard ratio of 0.4; and the respective percentage of patients still alive were 8 and 3. Overall, quizartinib treatment resulted in an improved outcome and showed superiority when compared with the NCRI cohort [&lt;ulink linkID="1718838" linkType="Reference"&gt;1718838&lt;/ulink&gt;]. In June 2017, further clinical data were presented at the 22nd EHA Annual Congress in Madrid, Spain. Significantly greater remission rates consisting mainly of complete remission without normal blood counts were observed in quizartinib-treated patients versus NCRI patients (40 versus 3%; adjusted odd ratio 0.05, p &amp;lt; 0.0001), and also quizartinib-treated patients showed improved median overall survival (140 versus 54 days, adjusted hazard ratio = 0.38; p &amp;lt; 0.0001). A landmark analysis revealed that 18-month survival was significantly greater in the SCT group versus non-SCT group (29 versus 7%, adjusted HR = 0.36, p = 0.0005) [&lt;ulink linkID="1939407" linkType="Reference"&gt;1939407&lt;/ulink&gt;]. In December 2017, further data were presented at the 59th ASH Annual Meeting and Exposition in Atlanta, GA. On DNA methylation landscape of FLT3- ITD AML blasts, treatment with quizartinib demonstrated a minimal impact; and only minimal epigenetic differences were observed when a direct comparison was done of baseline and post-treatment. Cytotoxic and differentiation responses were achieved in immunohistochemistry and flow cytometry analysis with no clear separation in a unsupervised correspondence analysis of high variance CpGs and scare number of differentially methylated regions both before and after treatment [&lt;ulink linkID="1988490" linkType="Reference"&gt;1988490&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I AML studies&lt;/subtitle&gt;In June 2018, an open-label, single group assigned, non-randomized, two-part, phase I study (&lt;ulink linkID="342397" linkType="Protocol"&gt;NCT03552029&lt;/ulink&gt;; DS3032-A-U105) to evaluate the safety and efficacy of &lt;ulink linkID="33494" linkType="Drug"&gt;milademetan&lt;/ulink&gt; in combination with quizartinib (AC-220) in patients (expected n =156) with FLT3-ITD mutant AML including primary AML or secondary to MDS that were relapsed/refractory, or newly diagnosed and unfit for intensive chemotherapy was to begin later that month. The primary endpoint was to determine the number of participants with dose limiting toxicities and adverse events. At that time, the trial was to complete in October 2021. In August 2018, the trial was initiated [&lt;ulink linkID="2043914" linkType="Reference"&gt;2043914&lt;/ulink&gt;]. In December 2018, first patient was dosed and planned to enroll  approximately 110 patients in the US, Europe and Japan [&lt;ulink linkID="2105492" linkType="Reference"&gt;2105492&lt;/ulink&gt;]. In June 2019, the trial was ongoing [&lt;ulink linkID="2166873" linkType="Reference"&gt;2166873&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, clinical data from an open-label, randomized, phase I study which evaluated the effect of &lt;ulink linkID="44299" linkType="Drug"&gt;ketoconazole&lt;/ulink&gt; and &lt;ulink linkID="44292" linkType="Drug"&gt;fluconazole&lt;/ulink&gt; on the pharmacokinetics and safety of quizartinib dihydrochloride (AC-220) and its active metabolite, AC-886, in healthy volunteers (n = 93) were presented at the 22nd EHA Annual Congress in Madrid, Spain. Subjects were randomized (1:1:1) to receive ketoconazole (200 mg, bid) x 28 days + quizartinib (30 mg, single dose on day 8; arm 1), fluconazole (200 mg, bid) x 28 days + quizartinib (30 mg, single dose on day 8; arm 2), or placebo bid x 28 days + quizartinib (30 mg, single dose on day 8; arm 3). Mean plasma concentrations of quizartinib were increased in subjects treated with ketoconazole (versus placebo) and slightly increased in patients treated with fluconazole (versus placebo). Similar increases were reported for quizartinib + AC-886. The median time to reach Tmax was consistent between both groups at 4 h. Overall, adverse events (AEs) were comparable across all treatment groups. There were no serious AEs or deaths reported. Quizartinib coadministration with ketoconazole or fluconazole was well tolerated [&lt;ulink linkID="1939355" linkType="Reference"&gt;1939355&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2016, a clinical trial application was filed in China to develop the product as a class 1 imported drug for the potential treatment of AML [&lt;ulink linkID="1785293" linkType="Reference"&gt;1785293&lt;/ulink&gt;]. In September 2018, a non-randomized, single arm, phase I trial (CTR2018005; AC220-A-A103) was planned to evaluate the safety and metabolism of AC-220 in Chinese patients (expected n = 6-18) with AML. At that time, it was not yet open for participants recruitment [&lt;ulink linkID="2076983" linkType="Reference"&gt;2076983&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2013, phase I trials were underway in Japan for AML [&lt;ulink linkID="1365353" linkType="Reference"&gt;1365353&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2012, data were presented from a phase I study in patients (n = 76) with relapsed/refractory AML at the 54th ASH Meeting in Atlanta, GA. Treatment with quizartinib completely inhibited the phosphorylation of FLT3-ITD (on day 8 with 18 mg dose and on day 1 with 60 mg dose).  In patients with FLT3-ITD mutations, levels of phosphorylated FLT3 were reduced. The objective response rates were 53 and 13% in patients with FLT3-ITD (+) and FLT3-ITD (-) AML, respectively. The overall objective response rate was 30% and the median duration of response was 13.3 weeks with median overall survival duration of 14 weeks [&lt;ulink linkID="1346945" linkType="Reference"&gt;1346945&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2012, an open-label, single group assignment, phase I study (&lt;ulink linkID="82220" linkType="Protocol"&gt;NCT01468467&lt;/ulink&gt;, 2689-CL-0011) of the drug as a maintenance therapy in AML subjects (n = 30) who were treated with an allogeneic hematopoietic stem cell transplant was initiated in the US. The study was expected to complete in March 2015 [&lt;ulink linkID="1307873" linkType="Reference"&gt;1307873&lt;/ulink&gt;]. In December 2014, clinical data were presented from 13 patients at the 56th ASH Meeting in San Francisco, CA. Grade 3 gastric hemorrhage and grade 3 anemia  were the DLTs reported at 40 and 60 mg dose-levels, respectively. Only one patient had a relapse and MTD was not identified [&lt;ulink linkID="1618680" linkType="Reference"&gt;1618680&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2011, an open-label, single group assignment, phase I study (&lt;ulink linkID="79123" linkType="Protocol"&gt;NCT01390337&lt;/ulink&gt;, 2689-CL-0005) of the drug was initiated in combination with induction and consolidation chemotherapy in newly diagnosed AML patients (n = 58) in the US. The study was expected to complete in March 2014 [&lt;ulink linkID="1307886" linkType="Reference"&gt;1307886&lt;/ulink&gt;].  In December 2013, further data were presented at the 55th ASH Meeting in New Orleans, LA. Complete remission, complete remission with incomplete platelet recovery and complete remission with incomplete hematological recovery were shown by 11, 1 and 3 patients, respectively. The 40 mg for 14 days or 60 mg for 7 days dose was established as the MTD [&lt;ulink linkID="1503748" linkType="Reference"&gt;1503748&lt;/ulink&gt;], [&lt;ulink linkID="1507456" linkType="Reference"&gt;1507456&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2011, an open-label, US, single group assignment, phase I study (&lt;ulink linkID="79869" linkType="Protocol"&gt;NCT01411267&lt;/ulink&gt;, T2009-004) of the drug in combination with cytarabine and &lt;ulink linkID="3072" linkType="Drug"&gt;etoposide&lt;/ulink&gt; was initiated in relapsed acute lymphoblastic leukemia and AML patients (n = 39), including children. In June 2012, the study was expected to complete in August 2014 [&lt;ulink linkID="1307872" linkType="Reference"&gt;1307872&lt;/ulink&gt;].  In December 2012, data were presented from 17 patients from this dose-escalation (3 + 3) study at the 54th ASH Meeting in Atlanta, GA. Of 16 patients evaluable for response, complete response (CR), CR with incomplete platelet recovery, CR with incomplete neutrophil recovery, stable disease and progressive disease were observed in 1, 1, 3, 6 and 4 patients, respectively. The treatment regimen was found to be well tolerated. At that time, another patient was undergoing protocol therapy at 60 mg/m2/day [&lt;ulink linkID="1346880" linkType="Reference"&gt;1346880&lt;/ulink&gt;]; in August 2013, data were planned to be presented at ASH in December 2013 [&lt;ulink linkID="1464808" linkType="Reference"&gt;1464808&lt;/ulink&gt;]. In December 2013, further data  were presented at the 55th ASH Meeting in New Orleans, LA. Of the 18 patients evaluable for response, 3 patients showed complete response, 1 patient showed complete response with incomplete platelet recovery, 9 patients had stable disease and 5 patients showed disease progression. Patients with FLT3-ITD had greater improvement in blast count percentage and in survival when compared wild-type FLT3. Treatment with AC-220 + cytarabine and etoposide was well tolerated at 60 mg/m2/day dose [&lt;ulink linkID="1503749" linkType="Reference"&gt;1503749&lt;/ulink&gt;] [&lt;ulink linkID="1507456" linkType="Reference"&gt;1507456&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2011, the drug was listed as being in phase I development in  relapsed/refractory AML patients with FLT3 ITD-negative  mutation [&lt;ulink linkID="1192176" linkType="Reference"&gt;1192176&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2006 an IND was filed  [&lt;ulink linkID="741759" linkType="Reference"&gt;741759&lt;/ulink&gt;]. In April 2007, Ambit started dosing in a phase I trial of quizartinib dihydrochloride for relapsed or refractory AML. The multicenter, open-label study would assess the safety, tolerability, pharmacokinetics and pharmacodynamics of the drug in 20 to 40 patients. They would receive 12 mg of the drug daily for 14 days, followed by dose escalation up to the maximum tolerated dose. Quizartinib dihydrochloride's pharmacodynamics would be assessed by measuring Flt3 receptor phosphorylation and peripheral blood blast counts [&lt;ulink linkID="782108" linkType="Reference"&gt;782108&lt;/ulink&gt;]. In December 2007,  data were presented at the 49th ASH meeting in Atlanta, GA. 3 and 8 patients were enrolled in the 12 mg and 18 mg cohorts, respectively, and received a median of 1.5 courses of quizartinib dihydrochloride. The average plasma exposure at the 12 and 18 mg doses were 7.6 and 13.4 ng/ml on day 1, respectively, and 33 and 60 ng/ml by steady state, respectively. The terminal half-life was about 1 to 2.8 days. It was concluded that 12 and 18 mg doses were well absorbed and tolerated. The terminal half life  was long and steady state was reached between 8 and 14 days [&lt;ulink linkID="857916" linkType="Reference"&gt;857916&lt;/ulink&gt;]. In December 2008,  data were presented at the 50th ASH meeting in San Francisco, CA. To date 52 patients have been enrolled in the phase I study. Quizartinib dihydrochloride was well tolerated with only mild adverse events reported. Eleven evaluable patients showed four complete responses and seven partial responses; 73% of these after one cycle of treatment [&lt;ulink linkID="967674" linkType="Reference"&gt;967674&lt;/ulink&gt;]. Plasma exposure was sustained between 12 and 450 mg, and AC-886, an active metabolite of quizartinib dihydrochloride, was discovered in patient urine and plasma samples [&lt;ulink linkID="967983" linkType="Reference"&gt;967983&lt;/ulink&gt;]. In August 2009, further data were expected to be presented in December 2009 at the 51st ASH meeting in New Orleans, LA [&lt;ulink linkID="1036008" linkType="Reference"&gt;1036008&lt;/ulink&gt;]. In December 2009, similar clinical data were presented at the 51st ASH meeting in New Orleans, LA.  Quizartinib dihydrochloride demonstrated an acceptable safety profile and exhibited a half-life of approximately 1.5 days. AC-886 also demonstrated a similar potency and activity profile. The most frequently reported drug-related grade 1 to 3 adverse events (AEs) included nausea (9%), dysgeusia (7%), vomiting (7%), diarrhea (7%) and peripheral edema (8%). The MTD was 200 mg continuous dosing (CD) and DLT was 300 mg CD. Overall, 9 patients had achieved CR (2 CR, 5 CRi, and 2 CRp) and 14 patients achieved PR. Both the median duration of response (MDOR) and the overall median survival (MS) was reported as 14 weeks [&lt;ulink linkID="1059143" linkType="Reference"&gt;1059143&lt;/ulink&gt;], [&lt;ulink linkID="1062631" linkType="Reference"&gt;1062631&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other Studies&lt;/subtitle&gt;In September 2018, data from a parallel-design study which evaluated the relative bioavailability and dose proportionality of quizartinib tablet formulation, and its active metabolite, AC-886, in healthy volunteers, were presented at the 2018 ACCP Annual Meeting in Bethesda, MD. Subjects (n = 80) were randomized into four treatment arms to receive single doses of quizartinib as tablet (30, 60 or 90 mg quizartinib 2HCl equivalent to 26.5, 53 or 79.5 mg free base, respectively) or as  po solution (60 mg only) in a fasted condition. The geometric least squares mean  ratios of quizartinib ranged between 0.97 to 1.10, indicating that the relative bioavailability of tablet to solution was within 10%. For Cmax, the 90% CIs were nearly contained within 80 to 125%. For AUClast and AUCinfinity, the 90% CIs were slightly wider (0.72 to 1.29 and 0.74 to 1.32, respectively). Similar trends were also seen for ratios for AC-886 and quizartinib + AC-886. Across treatments, the metabolite (AC-886) to parent (quizartinib) ratios for AUClast and AUCinfinity ranged from 0.50 to 0.62 [&lt;ulink linkID="2076842" linkType="Reference"&gt;2076842&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2018, a clinical trial, presumably in AML, had been initiated in China [&lt;ulink linkID="2082962" linkType="Reference"&gt;2082962&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Myelodysplastic syndrome and AML&lt;/subtitle&gt;By March 2014, an investigator-sponsored, phase II/III trial (LI-1) had been initiated to evaluate quizartinib in combination with low-dose cytarabine in patients (expected n = 50) with previously untreated AML or myelodysplastic syndrome (MDS) patients over the age of 60 who were not suited for standard induction chemotherapy [&lt;ulink linkID="1537429" linkType="Reference"&gt;1537429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2018, the &lt;ulink linkID="23382" linkType="Company"&gt;MD Anderson Cancer Center&lt;/ulink&gt;, in collaboration with &lt;ulink linkID="20519" linkType="Company"&gt;National Cancer Institute&lt;/ulink&gt;, planned to initiate an  open-label, single-group assigned, phase I/II trial (&lt;ulink linkID="352702" linkType="Protocol"&gt;NCT03661307&lt;/ulink&gt;; 2018-0394; NCI-2018-01789; P30CA016672)  in the US in February 2019, in patients (expected n = 52) with untreated or relapsed FLT3-ITD mutated AML or myelodysplastic syndrome, to assess the efficacy of the drug in combination with &lt;ulink linkID="13239" linkType="Drug"&gt;decitabine&lt;/ulink&gt;. At that time, the trial was expected to complete in January 2020 [&lt;ulink linkID="2071165" linkType="Reference"&gt;2071165&lt;/ulink&gt;]. In October 2018, the trial was initiated [&lt;ulink linkID="2071165" linkType="Reference"&gt;2071165&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2013, an investigator-sponsored, open label, phase I/II trial (&lt;ulink linkID="72140" linkType="Protocol"&gt;NCT01236144&lt;/ulink&gt;; AML-18; SPON 845-10, 2010-021444-18, 10/MRE09/27) to evaluate quizartinib in combination with &lt;ulink linkID="16758" linkType="Drug"&gt;Plerixafor&lt;/ulink&gt; or &lt;ulink linkID="54694" linkType="Drug"&gt;ganetespib&lt;/ulink&gt; was initiated in in older patients (expected n = 90) with AML and high risk myelodysplastic syndrome. The trial was expected to be completed in August 2014 [&lt;ulink linkID="1537488" linkType="Reference"&gt;1537488&lt;/ulink&gt;]; in December 2013, preliminary data were presented at the 55th ASH Meeting in New Orleans, LA. In March 2014, a total of 55 patients were enrolled [&lt;ulink linkID="1537429" linkType="Reference"&gt;1537429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solid tumors&lt;/subtitle&gt;In May 2011, the drug was listed as being in phase I development for gastrointestinal stromal tumor and melanoma  on Ambit's pipeline [&lt;ulink linkID="1192176" linkType="Reference"&gt;1192176&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2007, a phase I monotherapy trial in solid tumors was being planned [&lt;ulink linkID="857916" linkType="Reference"&gt;857916&lt;/ulink&gt;]; and in January 2010, the open-label, dose-finding, safety and tolerability phase I study  (&lt;ulink linkID="63420" linkType="Protocol"&gt;NCT01049893&lt;/ulink&gt;; AC220-004) began in patients (n = 45) with advanced solid tumors in the US. The primary endpoint was   the safety and tolerability of quizartinib dihydrochloride given once daily for 28 days.  The study was expected to complete in November 2011 with final data collected in October 2011 [&lt;ulink linkID="1072476" linkType="Reference"&gt;1072476&lt;/ulink&gt;]; in May 2011,   phase I development was ongoing [&lt;ulink linkID="1192176" linkType="Reference"&gt;1192176&lt;/ulink&gt;]. In April 2012, the study was ongoing   [&lt;ulink linkID="1072476" linkType="Reference"&gt;1072476&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2019, preclinical data were presented at the 2019 AACR Annual Meeting in Atlanta, GA. Quizartinib and its active metabolite, AC-886, bound to FLT3 with high affinity, with Kd values of 3.3 and 1.1 nM, respectively. Compared to &lt;ulink linkID="2764" linkType="Drug"&gt;midostaurin&lt;/ulink&gt; and &lt;ulink linkID="86751" linkType="Drug"&gt;gilteritinib&lt;/ulink&gt;, quizartinib showed potent antitumor activity in the MV4-11 xenograft model, with tumor growth inhibition (TGI) of 50, 95 and 100% at 0.3, 1 and 3 mg/kg dose, respectively, and EC50 of 0.86 mg/kg [&lt;ulink linkID="2134151" linkType="Reference"&gt;2134151&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2018, in vivo data were presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA. In MV-4011 iv xenograft model, quizartinib + milademetan improved survival with no animal deaths. In a patient-derived murine model of treatment-resistant AML (FLTD3-ITD-positive + D835 mutation/p53 wild-type), quizartinib + milademetan significantly extended survival [&lt;ulink linkID="2098752" linkType="Reference"&gt;2098752&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2018, preclinical data were presented at the 23rd EHA Annual Congress in Stockholm, Sweden. In FLT3-ITD mutant/P53 wild-type AML cell lines, treatment with quizartinib + milademetan combination showed highly synergistic apoptotic activity, and synergistically reduced phosphorylation levels of FLT3 and its downstream proteins, downregulated antiapoptotic protein Mcl-1, and further triggered apoptosis induction. In a MOLM-13 sc xenograft model, treatment with po quizartinib (0.5 or 1 mg/kg) and milademetan (25 or 50 mg/kg) over 12 days showed a reduction in tumor volume relative to single agents or vehicle controls  [&lt;ulink linkID="2045752" linkType="Reference"&gt;2045752&lt;/ulink&gt;], [&lt;ulink linkID="2041921" linkType="Reference"&gt;2041921&lt;/ulink&gt;]; in July 2018, the combination was listed as being in preclinical development for AML in the US [&lt;ulink linkID="2082962" linkType="Reference"&gt;2082962&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2011, preclinical data in c-Cbl-associated malignant myeloproliferative diseases were presented at the 53rd ASH meeting in San Diego, CA. Quizartinib dihydrochloride (10mg/kg) caused a marked decrease in the WBC counts of both c-Cbl(C379A) mice and C57BL/6.CD45.1 mice repopulated with bone marrow from c-Cbl(C379A) mice. In contrast, the WBC counts in the vehicle groups remained constantly high. A significant reduction (&amp;gt; 2-fold) in spleen weight and a marked decrease in the myeloid invasiveness into peripheral organs were also observed [&lt;ulink linkID="1244982" linkType="Reference"&gt;1244982&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2011, data from studies of quizartinib plus chemotherapy performed in MV4-11 solid tumor flank model of SCID mice were presented at the 53rd ASH meeting in San Diego, CA. Low dose of quizartinib dihydrochloride plus cytarabine was safe and showed additive/synergistic efficacy, with a remission rate of 30% (complete cure rate of 20%). Sub-optimal dose of quizartinib dihydrochloride (0.5 mg/kg) plus 5 + 3 combination of cytarabine + daunorubicin provided an added benefit in decreasing the tumor burden. The combination of high dose quizartinib dihydrochloride (10 mg/kg/day) plus 5+ 3 therapy provided a longer sustained complete tumor regression when compared with quizartinib dihydrochloride alone [&lt;ulink linkID="1242306" linkType="Reference"&gt;1242306&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In various FLT3 or KIT leukemia cell models tested,  quizartinib dihydrochloride targeted mutant-KIT and -FLT3 isoforms with distinct inhibitory activities, depending on the mutation’s location and aminoacid substitution. The compound showed resistance towards some kinase domain 2 mutations [&lt;ulink linkID="1150344" linkType="Reference"&gt;1150344&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2010, preclinical data were presented at the 101st AACR meeting in Washington DC. In MV4-11, MOLM-14, SEM-K2 and RS4; 11 AML cell lines, quizartinib dihydrochloride inhibited proliferation with IC50 values of 0.3, 0.1, 0.4 and &amp;gt; 10000 nM, respectively. In MV4-11 xenograft tumors, quizartinib dihydrochloride (1 or 10 mg/kg) inhibited downstream signalling of phosphorylated FLT3 and induced apoptosis in a dose- and time-dependent manner [&lt;ulink linkID="1088933" linkType="Reference"&gt;1088933&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2009, preclinical data were presented at the 100th AACR meeting in Denver, CO, which showed quizartinib dihydrochloride increased survival time and tumor burden in a mouse leukemia model [&lt;ulink linkID="997048" linkType="Reference"&gt;997048&lt;/ulink&gt;]. Further data presented showed quizartinib dihydrochloride's pharmacokinetics were dose dependent and the compound exhibited better potency and selectivity than first-generation  Flt3 inhibitors [&lt;ulink linkID="993975" linkType="Reference"&gt;993975&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, preclinical data on AB-460 were presented at the 99th AACR meeting in San Diego, CA. &lt;ulink linkID="25451" linkType="Company"&gt;UCSD&lt;/ulink&gt; and &lt;ulink linkID="14166" linkType="Company"&gt;Salk&lt;/ulink&gt; presented in vitro data on AB-460, the sister compound of quizartinib dihydrochloride. AB-460 potently inhibits Flt3 phosphorylation in the Ba/F3 murine pro-B cell line with an IC50 value of 1.9 nM [&lt;ulink linkID="896285" linkType="Reference"&gt;896285&lt;/ulink&gt;]. In September 2009, further data were published on the same series. AB-460 and AB-530 exhibited good oral availability in rats and potent tumor growth inhibition in a mouse xenograft model  [&lt;ulink linkID="1075914" linkType="Reference"&gt;1075914&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2007, preclinical data were presented at the 49th ASH meeting in Atlanta, GA. Quizartinib dihydrochloride inhibits proliferation of MV4-11 cells with an IC50 of 0.3nM. In the mouse MV4-11 xenograft model, tumor regression was observed at 3 mg/kg and tumor growth inhibition was observed at 1 mg/kg. The terminal half life was found to be 5.7 h in rats and 5.9 h in dogs [&lt;ulink linkID="857916" linkType="Reference"&gt;857916&lt;/ulink&gt;]. In December 2008,  similar preclinical data were reported at the 50th ASH meeting in San Francisco, CA [&lt;ulink linkID="967563" linkType="Reference"&gt;967563&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2006,  data were presented at the 19th International Medicinal Chemistry Symposium in Istanbul, Turkey. Another compound in the series, AB-460, inhibited Flt3 autophosphorylation in MV4-11 cells with a Kd value of 2 nM and an IC50 value of 0.3 nM. The compound showed specificity for Flt3, Kit, Ret and PDGFR kinases (&amp;lt; 10 nM) in a panel of 170 kinase assays. In mice, AB-460 (10 mg/kg po) showed a Cmax value of 1 microM and a half-life of 3 to 4 h [&lt;ulink linkID="689583" linkType="Reference"&gt;689583&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2005, preclinical data on Flt3 tyrosine kinase inhibitors were presented at the 229th ACS meeting in San Diego, CA. One of the  lead compounds, AB-200434, inhibited Flt3 autophosphorylation in MV4,11 cells with a Kd of ~ 1 nM and an IC50 value of ~ 0.7 nM. When this compound (10 mg/kg ip) was administered to mice, it had a Cmax of 7 microM, a half-life of 4.3 h, was 99% plasma protein bound, had a total plasma concentration (Cp) greater than the IC90 value for 24 h and an unbound Cp over the IC90 value for 2 h. AB-200434 had Kd values of between 0.66 and 3.3 nM at a variety of Flt3 mutants. Out of 64 compounds assessed, 40% had high stability in human microsomes and 70% had high stability in mouse microsomes. None of the compounds assessed for potential liabilities showed significant inhibition of cytochrome P450 1A, 2C9, 2C19, 2D6 or 3A4. AB-200382, AB-200432 and AB-200434 (3 and 10 mg/kg ip bid) demonstrated efficacy in a mouse AML solid tumor xenograft animal model, while AB-200382, AB-200243 and AB-200434 (3 and 10 mg/kg ip bid) demonstrated anti-leukemic activity in a mouse AML xenograft model  [&lt;ulink linkID="587118" linkType="Reference"&gt;587118&lt;/ulink&gt;]. In April 2005, similar data on this series were presented at the 96th AACR meeting in Anaheim, CA. These inhibitors demonstrated a high affinity for wild-type and mutant forms of FLT3 in human AML, with Kd values in the range 0.15 to 50 nM, and specificity for FLT3, KIT and PDGFR kinases, compared across a panel 170 kinase assays. FLT3 receptor autophosphorylation and proliferation were dose-dependently blocked in MV4-11 cells (IC50 = 0.2 to 50 nM) [&lt;ulink linkID="594770" linkType="Reference"&gt;594770&lt;/ulink&gt;]. In March 2006, similar data were presented at the 231st ACS meeting in Atlanta, GA [&lt;ulink linkID="658479" linkType="Reference"&gt;658479&lt;/ulink&gt;], [&lt;ulink linkID="657118" linkType="Reference"&gt;657118&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In November 2018, &lt;ulink linkID="1060306" linkType="Company"&gt;Invivoscribe Technologies&lt;/ulink&gt; submitted the LeukoStrat CDx FLT3 mutation assay, developed in partnership with Daiichi Sankyo, to both  the Japanese Pharmaceuticals and Medical Devices Agency and the US FDA, as the companion diagnostic for quizartinib [&lt;ulink linkID="2096349" linkType="Reference"&gt;2096349&lt;/ulink&gt;], [&lt;ulink linkID="2099271" linkType="Reference"&gt;2099271&lt;/ulink&gt;]. In June 2019, the MHLW approved the LeukoStrat CDx FLT3 mutation assay as a companion diagnostic  for the treatment of FLT3-ITD positive relapse / refractory AML patients [&lt;ulink linkID="2166200" linkType="Reference"&gt;2166200&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, the EMA's PDCO adopted a positive opinion on a pediatric investigation plan (PIP) for quizartinib for treatment of acute myeloid leukemia [&lt;ulink linkID="1778058" linkType="Reference"&gt;1778058&lt;/ulink&gt;]. In February 2018, the the EMA's PDCO adopted a positive opinion on modifications to a PIP for the treatment of acute myeloid leukaemia [&lt;ulink linkID="2011926" linkType="Reference"&gt;2011926&lt;/ulink&gt;]. In July 2018, the EMA's Pediatric Committee adopted a positive opinion agreeing a pediatric investigation plan for treatment of acute myeloid leukaemia [&lt;ulink linkID="2062871" linkType="Reference"&gt;2062871&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2019-06-18T00:00:00.000Z</StatusDate><Source id="2165456" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2018-11-21T00:00:00.000Z</StatusDate><Source id="2097040" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2018-11-05T00:00:00.000Z</StatusDate><Source id="2090035" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2016-10-11T00:00:00.000Z</StatusDate><Source id="1806143" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2014-11-08T00:00:00.000Z</StatusDate><Source id="1610644" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2014-11-08T00:00:00.000Z</StatusDate><Source id="1610644" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2016-10-11T00:00:00.000Z</StatusDate><Source id="1806143" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2016-10-11T00:00:00.000Z</StatusDate><Source id="1806143" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2016-10-11T00:00:00.000Z</StatusDate><Source id="1806143" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2016-10-11T00:00:00.000Z</StatusDate><Source id="1806143" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2018-03-31T00:00:00.000Z</StatusDate><Source id="2082962" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2013-09-30T00:00:00.000Z</StatusDate><Source id="1537429" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2013-09-30T00:00:00.000Z</StatusDate><Source id="1537429" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2013-09-30T00:00:00.000Z</StatusDate><Source id="1537429" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2013-09-30T00:00:00.000Z</StatusDate><Source id="1537429" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2010-01-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29179">Ambit Biosciences Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2010-01-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29179">Ambit Biosciences Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2010-01-13T00:00:00.000Z</StatusDate><Source id="1072476" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2010-01-13T00:00:00.000Z</StatusDate><Source id="1072476" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2013-02-01T00:00:00.000Z</StatusDate><Source id="1365353" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2009-12-18T00:00:00.000Z</StatusDate><Source id="1064894" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2009-12-18T00:00:00.000Z</StatusDate><Source id="1064894" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29179">Ambit Biosciences Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2009-11-30T00:00:00.000Z</StatusDate><Source id="1942367" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29179">Ambit Biosciences Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2014-03-20T00:00:00.000Z</StatusDate><Source id="1537429" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29179">Ambit Biosciences Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2014-03-20T00:00:00.000Z</StatusDate><Source id="1537429" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29179">Ambit Biosciences Corp</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2015-10-29T00:00:00.000Z</StatusDate><Source id="1544128" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29179">Ambit Biosciences Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2014-04-08T00:00:00.000Z</StatusDate><Source id="1544128" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29179">Ambit Biosciences Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2014-04-08T00:00:00.000Z</StatusDate><Source id="1544128" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29179">Ambit Biosciences Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2011-05-17T00:00:00.000Z</StatusDate><Source id="1192176" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29179">Ambit Biosciences Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2014-04-08T00:00:00.000Z</StatusDate><Source id="1544128" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2016-01-29T00:00:00.000Z</StatusDate><Source id="1730984" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29179">Ambit Biosciences Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2009-11-30T00:00:00.000Z</StatusDate><Source id="1942367" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29179">Ambit Biosciences Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2009-11-30T00:00:00.000Z</StatusDate><Source id="1942367" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2009-12-18T00:00:00.000Z</StatusDate><Source id="1064894" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2016-12-16T00:00:00.000Z</StatusDate><Source id="1894090" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2016-10-11T00:00:00.000Z</StatusDate><Source id="1806143" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2016-08-15T00:00:00.000Z</StatusDate><Source id="1785293" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2014-11-08T00:00:00.000Z</StatusDate><Source id="1610644" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2014-11-08T00:00:00.000Z</StatusDate><Source id="1610644" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017506">Daiichi Sankyo Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2018-10-17T00:00:00.000Z</StatusDate><Source id="2083462" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29179">Ambit Biosciences Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2007-04-10T00:00:00.000Z</StatusDate><Source id="782108" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29179">Ambit Biosciences Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2005-03-17T00:00:00.000Z</StatusDate><Source id="587118" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2009-12-18T00:00:00.000Z</StatusDate><Source id="1064894" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2009-12-18T00:00:00.000Z</StatusDate><Source id="1064894" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="1017506">Daiichi Sankyo Co Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of FLT3-mutated acute myeloid leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-11-05T00:00:00.000Z</MileStoneDate><Source id="2090035" type="PR"/></Row><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="1017506">Daiichi Sankyo Co Ltd</OwnerCompany><Country id="JP">Japan</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of FLT3-mutated acute myeloid leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-11-05T00:00:00.000Z</MileStoneDate><Source id="2090035" type="PR"/></Row><Row><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><OwnerCompany id="1017506">Daiichi Sankyo Co Ltd</OwnerCompany><Country id="US">US</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of adult patients with relapsed/refractory FLT3-ITD AML</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-08-01T00:00:00.000Z</MileStoneDate><Source id="2058908" type="PR"/></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1017506">Daiichi Sankyo Co Ltd</OwnerCompany><Country id="US">US</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of relapsed/refractory acute myelogenous leukemia (AML)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2016-10-11T00:00:00.000Z</MileStoneDate><Source id="1806143" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1017506">Daiichi Sankyo Co Ltd</OwnerCompany><Country id="JP">Japan</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of FLT3-mutation positive acute myeloid leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-09-06T00:00:00.000Z</MileStoneDate><Source id="2071460" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1017506">Daiichi Sankyo Co Ltd</OwnerCompany><Country id="JP">Japan</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>FLT3 mutation-positive acute myeloid leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2018-08-03T00:00:00.000Z</MileStoneDate><Source id="2062137" type="SERIAL"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1017506">Daiichi Sankyo Co Ltd</OwnerCompany><Country id="JP">Japan</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of FLT3-mutation-positive AML</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate>2018-07-23T00:00:00.000Z</MileStoneDate><Source id="2057192" type="SERIAL"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29179">Ambit Biosciences Corp</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2009-03-23T00:00:00.000Z</MileStoneDate><Source id="1543632" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29179">Ambit Biosciences Corp</OwnerCompany><Country id="US">US</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2009-03-18T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29179">Ambit Biosciences Corp</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2009-02-09T00:00:00.000Z</MileStoneDate><Source id="989804" type="PR"/></Row><Row><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation><OwnerCompany id="1017506">Daiichi Sankyo Co Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2018-07-27T00:00:00.000Z</MileStoneDate><Source id="2062871" type="PR"/></Row><Row><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation><OwnerCompany id="1017506">Daiichi Sankyo Co Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2018-02-23T00:00:00.000Z</MileStoneDate><Source id="2011926" type="PR"/></Row><Row><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation><OwnerCompany id="1017506">Daiichi Sankyo Co Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2016-07-04T00:00:00.000Z</MileStoneDate><Source id="1778058" type="PR"/></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="1017506">Daiichi Sankyo Co Ltd</OwnerCompany><Country id="US">US</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of adult patients with relapsed/refractory FLT3-ITD acute myelogenous leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-11-21T00:00:00.000Z</MileStoneDate><Source id="2097040" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00762"><Name>Flt3 tyrosine kinase</Name><SwissprotNumbers><Swissprot>P36888</Swissprot><Swissprot>Q00342</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01208"><Name>Kit tyrosine kinase</Name><SwissprotNumbers><Swissprot>O97799</Swissprot><Swissprot>P05532</Swissprot><Swissprot>P10721</Swissprot><Swissprot>P43481</Swissprot><Swissprot>Q08156</Swissprot><Swissprot>Q28317</Swissprot><Swissprot>Q28889</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01531"><Name>PDGF receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1013295">Astellas Pharma Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1017506">Daiichi Sankyo Co Ltd</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="1032858">NeoGenomics Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1060306">Invivoscribe Technologies Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21864">University of Texas System</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="2">Drug - Screening/Evaluation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC(C)(C)c1cc(no1)NC(=O)Nc2ccc(cc2)c3cn4c5ccc(cc5sc4n3)OCCN6CCOCC6.Cl.Cl</Smiles><Smiles>CC(C)(C)c1cc(no1)NC(=O)Nc2ccc(cc2)NC(=O)c3c(cccn3)O</Smiles><Smiles>CC(C)(C)c1cc(no1)NC(=O)Nc2ccc(cc2)c3cn4c5ccc(cc5sc4n3)OCCN6CCOCC6</Smiles><Smiles>CC(C)(C)c1cc(no1)NC(=O)Nc2ccc(cc2)NC(=O)c3cn4c5ccccc5sc4n3</Smiles><Smiles>CC(C)(C)c1cc(no1)NC(=O)Nc2ccc(cc2)NC(=O)c3cc4ccccc4cn3</Smiles></StructureSmiles><Deals><Deal id="129089" title="Ambit and Astellas to codevelop and market Flt-3 kinase inhibitors for cancer and non cancer indications worldwide        "/><Deal id="149733" title="Genoptix to develop a diagnostic test for Ambit's FLT3 receptor tyrosine kinase clinical trials     "/><Deal id="242712" title="MD Anderson and Daiichi to accelerate the development of therapies for AML "/><Deal id="251447" title="Invivoscribe to develop LeukoStrat CDx FLT3 Mutation Assay for the development of Daiichi's quizartinib against AML in Japan  "/></Deals><PatentFamilies><PatentFamily id="132969" number="WO-2007109120" title="Imidazolothiazole compounds for the treatment of disease"/><PatentFamily id="1370125" number="WO-2009038757" title="Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)-imidazo-[2,1-b][1,3]-benzothiazol-2-yl]-phenyl}-urea, compositions thereof, and uses therewith"/><PatentFamily id="1489139" number="WO-2010132787" title="Methods of treating proliferative diseases"/><PatentFamily id="149527" number="WO-2011056764" title="Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles"/><PatentFamily id="1909628" number="WO-2011056939" title="Process for the preparation of imidazo[2,1-b][1,3]benzothiazole derivatives"/><PatentFamily id="1984520" number="WO-2009061446" title="Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease"/><PatentFamily id="2131346" number="WO-2010111172" title="Methods of treatment using combination therapy"/><PatentFamily id="2713558" number="WO-2014055397" title="Tablet containing composite with cyclodextrin"/><PatentFamily id="2929397" number="WO-2015063768" title="Methods of treating acute myeloid leukemia with a flt3 mutation"/><PatentFamily id="3308284" number="WO-2016133194" title="Combination method for treating cancer"/><PatentFamily id="574989" number="WO-2008005310" title="Detectable nucleic acid tag"/><PatentFamily id="670997" number="WO-2010054185" title="Phosphorylated FMS-related tyrosine kinase 3 biomarker assay"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="DiscoveRx Corp" id="1002510"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BioLineRx Ltd" id="1008903"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biokine Therapeutics Ltd" id="1011989"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Astellas Pharma Inc" id="1013295"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Daiichi Sankyo Co Ltd" id="1017506"/><CountAsOwner>11</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>11</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></drugRecordOutput>